中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2273 records (took 0.029 seconds)

    R-lansoprazole compositions and methods
    71.
    发明申请
    R-lansoprazole compositions and methods 审中-公开
    R-兰索拉唑组合物和方法

    公开(公告)号：US20030008903A1

    公开(公告)日：2003-01-09

    申请号：US10216962

    申请日：2002-08-12

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  William E. Yelle ,  Paul D. Rubin

    IPC: A61K031/4439

    CPC classification number: A61K31/4439

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) lansoprazole for the treatment of S ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Lansoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 使用光学纯的（+）兰索拉唑用于治疗人类S溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）兰索拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Methods of treating or preventing weight gain, obesity, and related disorders
    72.
    发明申请
    Methods of treating or preventing weight gain, obesity, and related disorders 有权
    治疗或预防体重增加，肥胖和相关疾病的方法

    公开(公告)号：US20020188029A1

    公开(公告)日：2002-12-12

    申请号：US10000806

    申请日：2001-12-04

    Applicant: Sepracor Inc.

    Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

    IPC: A61K031/137

    CPC classification number: A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

    Abstract translation: 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的额外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT 3拮抗剂。

    Desmethylolanzapine compositions and methods
    76.
    发明申请
    Desmethylolanzapine compositions and methods 失效
    去甲羟氮氮斑组合物和方法

    公开(公告)号：US20020082251A1

    公开(公告)日：2002-06-27

    申请号：US10026303

    申请日：2001-12-19

    Applicant: SEPRACOR INC.

    Inventor： William E. Yelle

    IPC: A61K031/55

    CPC classification number: A61K31/551

    Abstract: Methods and compositions are disclosed utilizing N-desmethylolanzapine for the treatment of psychosis in humans. N-Desmethylolanzapine exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. N-Desmethylolanzapine is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.

    Abstract translation: 公开了使用N-去甲基氯氮平治疗人类精神病的方法和组合物。 N-甲基羟基兰氮平显示与奥氮平相比，药物相互作用的责任减少，而奥氮平更可预测给药方案。 N-去甲基氯氮平还可用于治疗急性躁狂症，轻度焦虑症，焦虑症，精神分裂症，双相情感障碍，注意缺陷多动障碍，自闭症，过度侵略，药物滥用，抑郁症状和症状，抽搐障碍，功能性肠病 和真菌性皮炎。

    Olanzapine-N-oxide compositions and methods
    77.
    发明申请
    Olanzapine-N-oxide compositions and methods 审中-公开

    公开(公告)号：US20020065272A1

    公开(公告)日：2002-05-30

    申请号：US10016205

    申请日：2001-10-30

    Applicant: SEPRACOR INC.

    Inventor： William E. Yelle

    IPC: A61K031/5513

    CPC classification number: A61K31/5513 ,  A61K31/551 ,  Y10S514/81 ,  Y10S514/811 ,  Y10S514/812

    Abstract: Methods and compositions are disclosed utilizing olanzapine-N-oxide for the treatment of psychosis in humans. Olanzapine-N-oxide exhibits a lessened liability toward drug-drug interactions than olanzapine and a more predictable dosing regimen than olanzapine. Olanzapine-N-oxide is also useful for the treatment of acute mania, mild anxiety states, anxiety disorders, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder, autistic disorder, excessive aggression, substance abuse, depressive signs and symptoms, tic disorder, functional bowel disorder and fungal dermatitis.

    Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion
    78.
    发明申请
    Methods and compositions for treating depression and other disorders using optically pure (-)-bupropion 失效
    使用光学纯（ - ） - 安非他酮治疗抑郁症和其他疾病的方法和组合物

    公开(公告)号：US20020006965A1

    公开(公告)日：2002-01-17

    申请号：US09891266

    申请日：2001-06-27

    Applicant: Sepracor Inc.

    Inventor： James W. Young

    IPC: A61K031/135

    CPC classification number: A61K31/137 ,  A61K31/135

    Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain and other disorders.

    Abstract translation: 公开利用安非他酮的光学纯（ - ） - 异构体的方法和组合物，其是用于治疗抑郁症，帕金森病，肥胖，体重增加和其它障碍的有效药物。

Patent Agency Ranking